Lab tests with prognostic claims are poised to transform patient management and can differ significantly from the more familiar suite of diagnostic tests. The burgeoning utility of prognostic assays in patient management in a range of disease states, including diabetes, cancer, and liver disease will be discussed, with a focus on the Enhanced Liver Fibrosis test (ELF) as a predictor of liver disease progression in patients with Non-Alcoholic Steatohepatitis (NASH).
We invite you to join us for a new webinar with Dr. Katherine Soreng, PhD, as she provides guidance on the numerous benefits of prognostic assays in patient management.
Learning Objectives: At the completion of this presentation attendees should be able to:
- Describe the similarities and differences in prognostic vs. diagnostic testing
- Understand the role of prognostic testing for patient risk stratification
- Describe how the ELF blood test helps identify NASH patients at high risk of disease progression
Speaker:
Dr. Soreng completed her BS in Biology at the University of Washington in Seattle and her PhD in Immunology and Molecular Pathogenesis at Emory University in Atlanta, GA.
As an undergraduate, she conducted research on human herpes viruses, including clinical testing and diagnosis. She completed a 2-year post-doctoral fellowship at the Centers for Disease Control and Prevention, where she investigated pathogenic factors associated with measles virus infection.
Dr. Soreng currently heads Global Clinical Education for Laboratory Diagnostics at Siemens Healthineers. She writes and educates on a variety of clinical diagnostic disease states, including Infectious Disease, Liver Fibrosis, Cardiology, and Neurology.
